Skip to main content

Table 1 Patient’s clinical and histopathologic characteristics

From: DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers

   Number of patients, n (%) Subset with FU, n (%)
Total   122 (100.0) 77 (100.0)
Histologic subtype ccRCC 86 (70.5) 57 (74.0)
  pap. RCC 24 (19.7) 17 (22.1)
  chrom. RCC 3 (2.5) 2 (2.6)
  Mixed histology 5 (4.1) 1 (1.3)
  Other 4 (3.3) 0 (0)
Gender Female 43 (35.2) 27 (35.1)
  Male 79 (64.8) 50 (64.9)
Age (years) Median 64.5 65
  Min-Max 35–91 37–91
Metastasis M0 95 (77.9) 59 (76.6)
  M1 27 (22.1) 18 (23.4)
  NA 0 (0.0)  
Lymph node status N0 107 (87.7) 70 (90.9)
  N1 15 (12.3) 7 (9.1)
Tumor stage pT1 11 (9.0) 8 (10.4)
  pT1a 35 (28.7) 24 (31.2)
  pT1b 21 (17.2) 13 (16.9)
  pT2 8 (6.6) 6 (7.8)
  pT3 5 (4.1) 2 (2.6)
  pT3a 12 (9.8) 4 (5.2)
  pT3b 25 (20.5) 18 (23.4)
  pT3c 3 (2.5) 2 (2.6)
  pT4 1 (0.8) 0 (0.0)
  NA 1 (0.8) 0 (0.0)
Differentiation G1 24 (19.7) 14 (18.2)
  G1–2 16 (13.1) 10 (13.0)
  G2 62 (50.8) 42 (54.5)
  G2–3 9 (7.4) 5 (6.5)
  G3 11 (9.0) 6 (7.8)
State of disease* Localized 65 (53.3) 42 (54.5)
  Advanced 56 (45.9) 35 (45.5)
  NA 1 (0.8) 0 (0.0)
  1. Abbreviations: ccRCC clear cell renal cell carcinoma (RCC); pap. RCC papillary RCC; chrom. RCC chromophobe RCC; FU follow-up; NA not available
  2. *Localized disease defined as pT ≤ 2, N0, M0; Advanced disease defined as pT ≥ 3 and/or N+, M+